In a very recent press release, the company stated that it had completed the Phase III glioblastoma registration trial even though it had not been able to recruit the final 17 patients because of a regulatory intervention that the company never shed any light on. The total number of patients in the trial of 331 should, according to the company, be enough to power the study. We await the results of this study as well as the results of other studies, which have yet to read out.